(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Recruiting now · Phase 2

Conditions studied: Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)

In brief

This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

Key facts

Study ID
NCT04996875
Run by
Cogent Biosciences, Inc.
People needed
140
Starts
2021-11-09
Expected to finish
2027-07-01
Last updated by the study team
2026-07-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.